Skip to main content
. Author manuscript; available in PMC: 2011 Oct 13.
Published in final edited form as: Nat Rev Clin Oncol. 2010 Dec 14;8(2):85–96. doi: 10.1038/nrclinonc.2010.189

Figure 2.

Figure 2

Targeting the PI3K/Akt/mTOR pathway to treat lymphoma. Pharmacological inhibition of mTORC1 with rapalogs has produced clinical responses in patients with relapsed non-Hodgkin lymphoma and classic Hodgkin lymphoma. Second-generation mTOR inhibitors and inhibitors of upstream molecules such as Akt and PI3K are currently in clinical trials. Frequently, cancer cells have several activated survival pathways, including the MEK/ERK, NF-κB, and JAK/STAT pathways. A combination of small molecules may be required to target these pathways. Abbreviations: ERK, extracellular signal-regulated kinase; JAK, Janus kinase; MEK, mitogen-activated protein kinase; mTOR, mammalian target of rapamycin; NF-κB, nuclear factor-kappa-B; PI3K, phosphatidylinositol 3-kinase; STAT, signal transducer and activator of transcription; TSC, tuberous sclerosis complex. Reproduced from Hematology by Anas Younes. Copyright 2009 from the American Society of Hematology (ASH). Reproduced with permission of American Society of Hematology (ASH) in the format Journal via Copyright Clearance Center.